WaveMan
WaveMan · Company
DSGN · Design Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

DSGN Design Therapeutics (DSGN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001807120
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
90
13F, latest reported quarter

Design Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Design Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
William Arsani
Director
SELL
2025-08-14 SECtraded 2025-08-13
217,627
$1.1M
+94.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (5 buys, 1 sale), the last on Aug 9, 2024.
  • -5.2% median (-6.9% mean) 90-day return after 5 previous buys.
  • The trade is 21.8% of the 1,000,000 shares held after it.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director William Arsani sold about $1.1M of DSGN on Aug 13, 2025, the largest insider sale at the company since 2024; 90 funds added in the latest 13F quarter.
William Arsani
Director
SELL
2025-08-14 SECtraded 2025-08-13
345,000
$1.8M
+94.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (5 buys, 1 sale), the last on Aug 9, 2024.
  • -5.2% median (-6.9% mean) 90-day return after 5 previous buys.
  • The trade is 13.0% of the 2,655,000 shares held after it.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director William Arsani sold about $1.8M of DSGN on Aug 13, 2025, the largest insider sale at the company since 2024; 90 funds added in the latest 13F quarter.
Prasad Deepa
Director
SELL
2024-12-19 SECtraded 2024-12-18
3,806
$23.9K
+65.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 29, 2023.
  • The trade is 19.0% of the 20,000 shares held after it.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Prasad Deepa sold about $23.9K of DSGN on Dec 18, 2024; 90 funds added in the latest 13F quarter.
William Arsani
Director
SELL
2024-08-12 SECtraded 2024-08-09
814,874
$3.5M
+134.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 29, 2023.
  • -5.2% median (-6.9% mean) 90-day return after 5 previous buys.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director William Arsani sold about $3.5M of DSGN on Aug 9, 2024, the largest insider sale at the company since 2022; 90 funds added in the latest 13F quarter.
Schmid John P.
Director
BUY
2024-03-25 SEC
17,809
$66.6K
+189.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 22, 2024.
  • The trade is 66.0% of the 26,965 shares held after it.
  • 1 other insider bought within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schmid John P. bought about $66.6K of DSGN on Mar 25, 2024; 1 other insider bought within 30 days and 90 funds added in the latest 13F quarter.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 22 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
90 funds bought in last quarter
more than 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.4% of the float short (float per yahoo 2026-10-27) · 12.0 days to cover · settled 2026-10-15
more than 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch DSGN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+81.4%12M
+0%+60%+120%+180%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DSGN: institutional holders (13F)

13F holdings, latest reported quarter
SR One Capital Management, LP
6,526,476 sh
$94.4M
Logos Global Management LP
3,000,000 sh
$43.4M
BAKER BROS. ADVISORS LP
2,678,430 sh
$38.8M
Driehaus Capital Management LLC
2,661,115 sh
$38.5M
BlackRock, Inc.
2,660,024 sh
$38.5M

Congress trades in DSGN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DSGN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

DSGN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$345.1K position · as of 2026-07-31
0.7%
AlphaCentric Life Sciences and Healthcare Fund
$311.6K position · as of 2026-06-30
0.7%
iShares Genomics Immunology and Healthcare ETF
$996.4K position · as of 2026-07-31
0.5%
ALPS Medical Breakthroughs ETF
$666.2K position · as of 2026-05-31
0.4%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.4M position · as of 2026-05-31
0.3%
Driehaus Micro Cap Growth Fund
$2.0M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
1
Phase 2
1 active
1
Multi-phase
1 active
What changed recently
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
2026-09-29 · Completion moved 2026-09 → 2027-12
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 90 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DSGN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$55.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-34.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-32.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-8.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0n/an/a
Operating income-$79.5M-$62.4M-$78.2M-$67.6M
Net income-$69.8M-$49.6M-$66.9M-$63.3M
EPS (diluted)-1.22-0.88-1.19-1.14
Operating cash flow-$54.4M-$43.1M-$58.6M-$51.3M
Cash$16.9M$22.6M$21.2M$26.5M
SEC XBRL, fiscal years, as known on 2026-10-28

DSGN Stock Sonar score 3/7 axes

Find similar shapesCompare

DSGN ranks highest on institutional and government (64th percentile) and profitability (61st), and lowest on risk and compliance (33rd), among Pharma & Biotech peers.

Profitability
61
Inputs
  • Return on equity-34.1% · 65 pct, sector of 545
  • Return on assets-32.3% · 58 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.0% · 61 pct, sector of 576
Institutional and government
64
Inputs
  • Funds adding, latest quarter90 · 64 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
33
Inputs
  • Short interest, % of float+18.4% · 17 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+10.7% · 49 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies